Nuvectis Pharma Inc. (NVCT): Price and Financial Metrics
GET POWR RATINGS... FREE!
NVCT Stock Price Chart Interactive Chart >
NVCT Price/Volume Stats
| Current price | $12.45 | 52-week high | $20.92 |
| Prev. close | $11.95 | 52-week low | $6.02 |
| Day low | $11.90 | Volume | 41,900 |
| Day high | $12.45 | Avg. volume | 66,685 |
| 50-day MA | $9.93 | Dividend yield | N/A |
| 200-day MA | $9.07 | Market Cap | 183.66M |
Nuvectis Pharma Inc. (NVCT) Company Bio
Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.
Latest NVCT News From Around the Web
Below are the latest news stories about NUVECTIS PHARMA INC that investors may wish to consider to help them evaluate NVCT as an investment opportunity.
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research MeetingFort Lee, NJ, March 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2023 American Association for Cancer Research Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Flori |
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth ConferenceFORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference. Event 35th Annual Roth Conference Date March 14, 2023 Time 12:00 PM Pacific Time (3:00 PM Easter |
Bullish insiders bet US$1.1m on Nuvectis Pharma, Inc. (NASDAQ:NVCT)When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business HighlightsNXP800 Granted Fast Track Designation for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian CarcinomaENGOT and GOG Foundation to Lead the NXP800 Phase 1b Clinical Trial in Ovarian Cancer (Study Commencement Pending) NXP900 IND Submission and Phase 1 Study Commencement Expected in 1H 2023 FORT LEE, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ |
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers CongressTreatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models of ARID1a-mutated ovarian carcinoma, superior to treatment with cisplatinFort Lee, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today provided highlights fr |
NVCT Price Returns
| 1-mo | 24.87% |
| 3-mo | 69.39% |
| 6-mo | 59.41% |
| 1-year | 106.47% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 66.00% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...